// App-Quantinova.ai

1020 : Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.

Researchers

Presenter

  • Carlo Palmieri

Principal Investigators

  • Hannah M. Linden

  • Stephen Birrell

  • Elgene Lim

  • Lee S. Schwartzberg

  • Hope S. Rugo

  • Patrick Wayne Cobb

  • Kirti Jain

  • Charles L. Vogel

  • Joyce O'Shaughnessy

  • Stephen R. D. Johnston

  • Robert H. Getzenberg

  • K. Gary Barnette

  • Mitchell S. Steiner

  • Adam Brufsky

  • Beth Overmoyer

Medical Centers

  • Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom

  • University of Washington Seattle Cancer Care Alliance, Seattle, WA

  • Wellend Health/Burnside Hospital, Toorak Gardens, Australia

  • Olivia Newton-John Cancer and Wellness Centre, Melbourne, Australia

  • West Cancer Center, Memphis, TN

  • University of California, San Francisco, San Francisco, CA

  • Frontier Cancer Center, Billings, MT

  • Ashland Bellefonte Cancer Center, Ashland, KY

  • Sylvester At Deerfield Beach, Deerfield Beach, FL

  • Texas Oncology/Baylor Sammons Cancer Center/US Oncology, Dallas, TX

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Veru Inc, Miami, FL

  • GTx, Inc., Memphis, TN

  • NSABP/NRG Oncology and the UPMC Hillman Cancer Center, Pittsburgh, PA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United Kingdom

  • United States

  • Australia

Companies

  • GTx, Inc. (Oncternal

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enobosarm

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • II

Study Id's

  • NCT02463032

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved